FOXO4-DRI
FOXO4-DRI (D-Retro-Inverso Senolytic Peptide)
Senolytic Peptide for Longevity
What is FOXO4-DRI?
FOXO4-DRI is a synthetic senolytic peptide engineered to selectively eliminate senescent cells, commonly referred to as zombie cells, from aging tissues. Senescent cells are cells that have permanently exited the cell cycle in response to damage, oncogenic stress, or replicative exhaustion. Rather than dying through programmed cell death (apoptosis), they persist and secrete a destructive mixture of pro-inflammatory cytokines, proteases, and growth factors known as the senescence-associated secretory phenotype (SASP). Accumulation of senescent cells is a major driver of age-related tissue dysfunction, chronic inflammation, and organ decline.
The peptide is designed using D-retro-inverso (DRI) topology, meaning it is built from D-amino acids arranged in a reversed sequence relative to the native FOXO4 protein. This configuration confers exceptional resistance to enzymatic degradation by proteases, giving FOXO4-DRI superior in vivo stability compared to peptides constructed from standard L-amino acids. The DRI designation is integral to the molecule's function, not merely a nomenclatural detail.
The mechanism of action targets the molecular survival circuit that keeps senescent cells alive. The transcription factor FOXO4 interacts with the tumor suppressor p53 within senescent cells, sequestering p53 in the nucleus and preventing it from triggering apoptosis. FOXO4-DRI competitively disrupts this FOXO4-p53 interaction. Once unbound, p53 translocates from the nucleus to the cytoplasm, where it activates the pro-apoptotic protein BAX, initiating the execution phase of apoptosis specifically in senescent cells. In vitro studies demonstrated an 11.73-fold difference in cytotoxicity between senescent and healthy control cells, confirming that healthy cells are largely spared.
Published animal studies have shown compelling results. In naturally aged and chemotherapy-induced aging mouse models, FOXO4-DRI treatment restored physical fitness, improved fur density and appearance, and improved renal function. Studies on aged male mice showed that FOXO4-DRI improved the testicular microenvironment and partially restored testosterone secretion by eliminating senescent Leydig cells. A 2025 study in Nature Communications further characterized the structural basis of the FOXO4-p53 interaction and validated the peptide's mechanism using biophysical methods.
Research Supply
Source high-purity FOXO4-DRI for your research
Dosage Guide
Route: Subcutaneous injection (investigational human use)
Dosing Schedule
| Period | Dose |
|---|---|
| Animal study protocol | 5 mg/kg intraperitoneally, every other day for 3 total administrations over 5 days |
| Investigational human range | 1-5 mg subcutaneous, 2-3 times per week during active cycle |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|
Cycling Protocol
1-2 weeks
Approximately 3 months (quarterly cycle)
Investigational human protocols report quarterly cycles of 1-2 weeks of active administration
Administration Tips
- Reconstitute lyophilized FOXO4-DRI with bacteriostatic water or sterile saline
- Due to the D-amino acid composition, the peptide is stable under standard refrigeration (2-8 degrees Celsius) for extended periods
- Protect from light during storage
- Human investigational protocols typically cycle 1-2 weeks per quarter
- Human dosing has not been established through clinical trials; all protocols are extrapolated from animal research
Risks & Side Effects
Commonly Reported
Serious Risks
Off-target apoptosis in healthy cells
Selectivity established in vitro but human tissue response at pharmacological doses is uncertain.
Inflammatory surge
Simultaneous release of SASP factors as senescent cells die may produce an inflammatory surge similar to a Herxheimer-type reaction.
Interaction with cancer treatments
Unknown interactions with active cancer treatments; apoptosis modulation may interfere with chemotherapy mechanisms.
Immune dysregulation
Senescent cells serve signaling functions in wound healing and tissue homeostasis; wholesale clearance may disrupt these processes.
Contraindications
- Active cancer treatment (theoretical interaction with apoptosis-based therapeutic mechanisms)
- Post-surgical recovery (senescent cells contribute to acute wound healing signaling)
- Pregnancy or breastfeeding (no data; apoptosis induction is contraindicated in fetal development contexts)
- Known hypersensitivity to the peptide or formulation excipients
- Severe immunodeficiency (SASP clearance may alter immune signaling unpredictably)
Frequently Asked Questions
Related Peptides
Experts Covering FOXO4-DRI
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. FOXO4-DRI has not been approved by the FDA for any medical condition. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.